A Single-center, Randomized, Double-blind (for OPC-61815 and Placebo), Placebo- and Moxifloxacin Positive-controlled, 4-Period Crossover Trial to Evaluate the Effect of Single Intravenous Administration of OPC-61815 at 16 and 32 mg on QT/QTc Interval in Healthy Male Subjects.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2018
At a glance
- Drugs Tolvaptan (Primary) ; Moxifloxacin
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 21 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.
- 15 Aug 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.